1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Ingrassia, Rosaria ^a   Lanzillotta, Annamaria ^a   Sarnico, Ilenia ^a   Benarese, Marina ^a   Blasi, Francesco ^b   Borgese, Laura ^c   Bilo, Fabjola ^c   Depero, Laura ^c   Chiarugi, Alberto ^b   Spano, Pier Franco ^a,d   Pizzi, Marina ^a,d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DEFEROXAMINE; DIVALENT METAL TRANSPORTER 1 ISOFORM 1B; HISTONE H3; IRON; LYSINE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; CATION TRANSPORT PROTEIN; GLUCOSE; HISTONE; ISOPROTEIN; OXYGEN; SOLUTE CARRIER FAMILY 11 (PROTON COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2; SOLUTE CARRIER FAMILY 11- (PROTON-COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN ISCHEMIA; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; EMBRYO; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IRON CHELATION; IRON RESPONSIVE ELEMENT; IRON TRANSPORT; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PROMOTER REGION; TRANSACTIVATION; UPREGULATION; ACETYLATION; ANIMAL; CELL DEATH; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; MALE; METABOLISM; NERVE CELL; PATHOLOGY; TRANSCRIPTION INITIATION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALIA; MUS;

ACETYLATION; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN ISCHEMIA; CATION TRANSPORT PROTEINS; CELL DEATH; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GLUCOSE; HISTONES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACELLULAR SPACE; IRON; LYSINE; MALE; MICE; NEURONS; OXYGEN; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; STROKE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84861561342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038019     Document Type: Article

References (63)

1. Connor JR, Ghio AJ, (2009) The impact of host iron homeostasis on disease. Biochim Biophys Acta 1790 (7): 581-2.
2. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (11): 863-73.
3. Youdim MB, Stephenson G, Ben Shachar D, (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, deferoxamine and VK-28. Ann NY Acad Sci 1012: 306-325.
4. Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH, (2007) Iron trafficking inside the brain. J Neurochem 103 (5): 1730-40.
5. Snyder AM, Connor JR, (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790 (7): 606-14.
6. Moos T, Morgan EH, (2004) The methabolism of neuronal iron and its pathogenic role in neurological disease. Ann NY Acad Sci 1012: 14-26.
7. Youdim MB, Grünblatt E, Mandel S, (1999) The pivotal role of Iron in NF-κB activation and nigrostriatal Dopaminergic Neurodegeneration. Ann NY Acad Sci 890: 7-25.
8. Jiang H, Luan Z, Wang J, Xie J, (2006) Neuroprotective effects of iron chelator Deferoxamine on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49 (6): 605-9.
9. Mandel S, Amit T, Bar-Am O, Youdim MB, (2007) Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 82: 348-360.
10. Zhang S, Wang J, Song N, Xie J, Jiang H, (2009) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. 9 Neurobiol Aging pp. 1466-76.
11. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, et al. (2011) Novel molecular targets of the multi-functional brain-permeable iron chelating drug M30 in mouse brain. Neuroscience 189: 345-58.
12. Gassen M, Youdim MB, (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol. 80 (4): 159-66.
13. Yang L, Zhang B, Yin L, Cai B, Shan H, et al. (2011) Tanshinone IIA prevented brain iron dyshomeostasis in cerebral ischemic rats. Cell Physiol Biochem 27 (1): 23-30.
14. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, et al. (2009) Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J Neurosci 29 (27): 8828-38.
15. Okauchi M, Hua Y, Keep RF, Morgenstern LB, Schallert T, et al. (2010) Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke 41 (2): 375-82.
16. Hill JM, Ruff MR, Weber RJ, Pert CB, (1985) Transferrin receptors in rat brain: Neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82: 4553-4557.
17. Faucheux BA, Hauw JJ, Agid Y, Hirsch EC, (1997) The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 749: 170-174.
18. Hirsch EC, (2009) Iron transport in Parkinson's disease. Parkinsonism Relat Disord (Suppl 3): S209-11.
19. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, et al. (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 (6641): 482-8.
20. Hidalgo C, Carrasco MA, Muñoz P, Núñez MT, (2007) A role for reactive oxygen/nitrogen species and iron on neuronal synaptic plasticity. Antioxid Redox Signal 9 (2): 245-55.
21. Burdo JR, Martin J, Menzies SL, Dolan KG, Romano MA, et al. (1999) Cellular distribution of iron in the brain of the Belgrade rat. Neuroscience 93 (3): 1189-96.
22. Wang XS, Ong WY, Connor JR, (2003) Quinacrine attenuates increases in divalent metal transporter-1 and iron levels in the rat hippocampus, after kainate-induced neuronal injury. Neuroscience 120 (1): 21-9.
23. Huang E, Ong WY, Connor JR, (2004) Distribution of divalent metal transporter-1 in the monkey basal ganglia. Neuroscience 128 (3): 487-96.
24. Vidal S, Belouchi AM, Cellier M, Beatty B, Gros P, (1995) Cloning and characterization of a second human NRAMP gene on chromosome 12q13. Mamm Genome 6 (4): 224-30.
25. Hubert N, Hentze MW, (2002) Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci USA 99 (19): 12345-50.
26. Haile J, (1999) Regulation of genes of iron metabolism by the iron response proteins. American Journal of the Medical Sciences 318, 230-240.
27. Pantopoulos K, (2004) Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 1012: 1-13.
28. Tabuchi M, Tanaka N, Nishida-Kitayama J, Ohno H, Kishi F, (2002) Alternative splicing regulates the subcellular localization of divalent metal transporter 1 isoforms. Mol Biol Cell 13 (12): 4371-87.
29. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, et al. (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 105 (47): 18578-83.
30. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, et al. (2001) Distribution of divalent metal transporter-1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 66: 1198-1207.
31. Du F, Qian ZM, Zhu L, Wu XM, Yung WH, et al. (2009) L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PLoS One 4 (2): e4593.
32. Lis A, Paradkar PN, Singleton S, Kuo HC, Garrick MD, et al. (2005) Hypoxia induces changes in expression of isoforms of the divalent metal transporter (DMT1) in rat pheochromocytoma (PC12) cells. Biochem Pharmacol 69 (11): 1647-55.
33. Li Z, Lai Z, Ya K, Fang D, Ho YW, et al. (2008) Correlation between the expression of divalent metal transporter 1 and the content of hypoxia-inducible factor-1 in hypoxic HepG2 cells. J Cell Mol Med 12 (2): 569-79.
34. Shah, YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ, (2009) Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metabolism 9: 152-164.
35. Wang D, Wang LH, Zhao Y, Lu YP, Zhu L, (2010) Hypoxia regulates the ferrous iron uptake and reactive oxygen species level via divalent metal transporter 1 (DMT1) Exon1B by hypoxia-inducible factor-1. IUBMB Life 62 (8): 629-36.
36. Qian ZM, Wu XM, Fan M, Yang L, Du F, et al. (2011) Divalent metal transporter 1 is a hypoxia-inducible gene. J Cell Physiol 226 (6): 1596-603.
37. Paradkar PN, Roth JA, (2006) Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by Retinoic acid. Biochemical J 394: 173-183.
38. Paradkar PN, Roth JA, (2006) Nitric oxide transcriptionally down-regulates specific isoforms of divalent metal transporter (DMT1) via NF-kappaB. J Neurochem 96 (6): 1768-77.
39. Xu H, Jiang H, Wang J, Xie J, (2010) Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 58 (2): 488-94.
40. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO, (2006) Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542 (1-3): 1-7.
41. Pizzi M, Spano P (2006) Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol 545 (1): 22-8.
42. Sarnico I, Lanzillotta A, Boroni F, Benarese M, Alghisi M, et al. (2009) NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischemia. J Neurochem 108 (2): 475-85.
43. Lanzillotta A, Sarnico I, Ingrassia R, Boroni F, Branca C, et al. (2010) The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis 1 (11): e96.
44. Yang XD, Tajkorshis E, Chen LF, (2010) Functional interplay between acetylation and methylation of the RelA subunit of NF-κB. Mol Cell Biol 30 (9): 2170-80.
45. Pizzi M, Boroni F, Bianchetti A, Moraitis C, Sarnico I, et al. (2002) Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. Eur J Neurosci 16 (12): 2342-50.
46. Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, et al. (2006) Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. 50 J Neurosci 26 pp. 12896-903.
47. Faraco G, Blasi F, Min W, Wang ZQ, Moroni F, et al. (2010) Brain ischemic preconditioning does not require PARP-1. Stroke 41 (1): 181-3.
48. Crenon I, Béraud C, Simard P, Montagne J, Veschambre P, et al. (1993) The transcriptionally active factors mediating the effect of the HTLV-I Tax transactivator on the IL-2R alpha kappa B enhancer include the product of the c-rel proto-oncogene. Oncogene 8 (4): 867-75.
49. Garrick MD, Kuo HC, Vargas F, Singleton S, Zhao L, et al. (2006) Comparison of mammalian cell lines expressing distinct isoforms of divalent metal transporter 1 in a tetracycline-regulated fashion. Biochem J 398 (3): 539-46.
50. Roth JA, Horbinski C, Feng L, Dolan KG, Higgins D, et al. (2000) Differential localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells. J Neurosci 20 (20): 7595-601.
51. Kuo HC, Smith JJ, Lis A, Zhao L, Gonsiorek EA, et al. (2004) Computer-identified nuclear localization signal in exon 1A of the transporter DMT1 is essentially ineffective in nuclear targeting. J Neurosci Res 76 (4): 497-511.
52. Chen LF, Mu Y, Greene WC, (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 21: 6539-6548.
53. Tacchini L, Fusar Poli D, Bernelli-Zazzera A, Cairo G, (2002) Transferrin receptor gene expression and transferrin-bound iron uptake are increased during post-ischemic rat liver reperfusion. Hepatology 36 (1): 103-11.
54. Burdo JR, Connor JR, (2003) Brain iron uptake and homeostatic mechanisms: an overview. Biometals 16 (1): 63-75.
55. Lee JY, Keep RF, He Y, Sagher O, Hua Y, et al. (2010) Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab 30 (11): 1793-803.
56. Lis A, Barone TA, Paradkar PN, Plunkett RJ, Roth JA, (2004) Expression and localization of different forms of DMT1 in normal and tumor astroglial cells. Brain Res Mol Brain Res 122 (1): 62-70.
57. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, et al. (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330 (3): 679-86.
58. Zhao Y, Rempe DA, (2011) Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab 31 (6): 1412-23.
59. Wu H, Wu T, Xu X, Wang J, Wang J, (2011) Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. J Cereb Blood Flow Metab 31 (5): 1243-50.
60. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB, (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444.
61. Semenza GL, (2011) Oxygen sensing, homeostasis, and disease.N Engl J Med 365 (6): 537-47.
62. Chew KC, ET, Tai YK, Tsang F, Lo SQ, et al. (2011) Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein: implications from neuronal cell death in Parkinson disease. J Biol Chem 286 (38): 33380-9.
63. Xu H, Jiang H, Wang J, Xie J, (2010) Rg1 protects iron-induced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23.5 cells. J Cell Biochem 111 (6): 1537-45.